Published in BMJ on January 20, 2007
Medicine. Moving toward transparency of clinical trials. Science (2008) 4.36
Conflicts of interest, authorship, and disclosures in industry-related scientific publications: the tort bar and editorial oversight of medical journals. Mayo Clin Proc (2009) 3.48
Reporting bias in medical research - a narrative review. Trials (2010) 2.44
Pharmacovigilance: methods, recent developments and future perspectives. Eur J Clin Pharmacol (2008) 2.24
Direct to consumer advertising of drugs in Europe. BMJ (2007) 1.46
Promoting transparency in pharmaceutical industry-sponsored research. Am J Public Health (2011) 1.46
What can we learn from drug marketing efficiency? BMJ (2008) 1.40
No short-cut in assessing trial quality: a case study. Trials (2009) 1.39
Challenges to physician-patient communication about medication use: a window into the skeptical patient's world. Patient Prefer Adherence (2011) 0.98
Has the hunt for conflicts of interest gone too far? Yes. BMJ (2008) 0.95
Dust diseases and the legacy of corporate manipulation of science and law. Int J Occup Environ Health (2014) 0.95
mPGES-1 deletion impairs diuretic response to acute water loading. Am J Physiol Renal Physiol (2009) 0.91
How do authors of systematic reviews deal with research malpractice and misconduct in original studies? A cross-sectional analysis of systematic reviews and survey of their authors. BMJ Open (2016) 0.90
Effective use of real-life events as tools for teaching-learning clinical pharmacology in a problem-based learning curriculum. Indian J Pharmacol (2015) 0.84
Ethics, economics and the regulation and adoption of new medical devices: case studies in pelvic floor surgery. BMC Med Ethics (2010) 0.81
Comparison of serious adverse events posted at ClinicalTrials.gov and published in corresponding journal articles. BMC Med (2015) 0.80
Mast cells are critical for protection against peptic ulcers induced by the NSAID piroxicam. PLoS One (2011) 0.78
Who has used internal company documents for biomedical and public health research and where did they find them? PLoS One (2014) 0.78
Medical ghost-writing. Mens Sana Monogr (2008) 0.77
Doctors and medical science. Australas Med J (2012) 0.75
Medical guidelines and performance measures: the need to keep them free of industry influence. Mens Sana Monogr (2008) 0.75
Early termination of drug trials. BMJ (2007) 0.75
Does administration of non-steroidal anti-inflammatory drug determine morphological changes in adrenal cortex: ultrastructural studies. Protoplasma (2010) 0.75
Rofecoxib-Induced Deleterious Effects Escape Detection by Organismal Performance Assays. J Pharm Negat Results (2016) 0.75
Adverse drug reactions monitoring: prospects and impending challenges for pharmacovigilance. Springerplus (2014) 0.75
FDA Policy and Cardiovascular Medicine. Circulation (2015) 0.75
Etoricoxib-induced life-threatening hyperkalemia and acute kidney dysfunction against the background of telmisartan and a low sodium diet. Int J Emerg Med (2010) 0.75
Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc (2010) 0.75
Separating the wheat from the chaff: essential information in therapeutics. Eur J Clin Pharmacol (2011) 0.75
Unbalanced reporting of benefits and harms in abstracts on rofecoxib. Eur J Clin Pharmacol (2010) 0.75
Pharmacoepidemiologic research in Australia: challenges and opportunities for monitoring patients with rheumatic diseases. Clin Rheumatol (2009) 0.75
Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA (2008) 12.36
Exposure to low-dose ionizing radiation from medical imaging procedures. N Engl J Med (2009) 11.51
An administrative claims measure suitable for profiling hospital performance on the basis of 30-day all-cause readmission rates among patients with heart failure. Circ Cardiovasc Qual Outcomes (2008) 6.00
Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA (2013) 5.27
The ADVANTAGE seeding trial: a review of internal documents. Ann Intern Med (2008) 4.70
Regulatory review of novel therapeutics--comparison of three regulatory agencies. N Engl J Med (2012) 4.50
Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006. JAMA (2010) 4.36
Reduction in acute myocardial infarction mortality in the United States: risk-standardized mortality rates from 1995-2006. JAMA (2009) 4.24
When choosing statin therapy: the case for generics. JAMA Intern Med (2013) 3.80
Avoidance of generic competition by Abbott Laboratories' fenofibrate franchise. Arch Intern Med (2012) 2.95
Use of fibrates in the United States and Canada. JAMA (2011) 2.82
Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance. Arch Intern Med (2009) 2.80
Maximizing profit and endangering health: corporate strategies to avoid litigation and regulation. Int J Occup Environ Health (2005) 2.75
American College of Occupational and Environmental Medicine (ACOEM): a professional association in service to industry. Int J Occup Environ Health (2007) 2.74
Hospital readmission performance and patterns of readmission: retrospective cohort study of Medicare admissions. BMJ (2013) 2.36
National patterns of risk-standardized mortality and readmission for acute myocardial infarction and heart failure. Update on publicly reported outcomes measures based on the 2010 release. Circ Cardiovasc Qual Outcomes (2010) 2.33
Health care insurance, financial concerns in accessing care, and delays to hospital presentation in acute myocardial infarction. JAMA (2010) 2.33
Sharing of clinical trial data among trialists: a cross sectional survey. BMJ (2012) 2.31
Physician attitudes toward industry: a view across the specialties. Arch Surg (2010) 2.29
Cumulative exposure to ionizing radiation from diagnostic and therapeutic cardiac imaging procedures: a population-based analysis. J Am Coll Cardiol (2010) 2.26
Ghostwriting: research misconduct, plagiarism, or fool's gold? Am J Med (2012) 2.19
Relationship between hospital readmission and mortality rates for patients hospitalized with acute myocardial infarction, heart failure, or pneumonia. JAMA (2013) 2.06
Advanced access scheduling outcomes: a systematic review. Arch Intern Med (2011) 2.06
Recent trends in chronic disease, impairment and disability among older adults in the United States. BMC Geriatr (2011) 2.02
Electronic health record components and the quality of care. Med Care (2008) 1.97
Generic atorvastatin and health care costs. N Engl J Med (2011) 1.95
Comparison of hospital risk-standardized mortality rates calculated by using in-hospital and 30-day models: an observational study with implications for hospital profiling. Ann Intern Med (2012) 1.90
Use of hospital-based acute care among patients recently discharged from the hospital. JAMA (2013) 1.88
Use of ezetimibe in the United States and Canada. N Engl J Med (2008) 1.85
Assessing the impact of screening colonoscopy on mortality in the medicare population. J Gen Intern Med (2011) 1.73
Cognitive decline among patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2009) 1.69
Acute myocardial infarction and congestive heart failure outcomes at specialty cardiac hospitals. Circulation (2007) 1.61
Study of neurontin: titrate to effect, profile of safety (STEPS) trial: a narrative account of a gabapentin seeding trial. Arch Intern Med (2011) 1.60
The cost of breast cancer screening in the Medicare population. JAMA Intern Med (2013) 1.53
Differences in patient survival after acute myocardial infarction by hospital capability of performing percutaneous coronary intervention: implications for regionalization. Arch Intern Med (2010) 1.52
Tamiflu: 14 flu seasons and still questions. BMJ (2013) 1.49
A historic moment for open science: the Yale University Open Data Access project and medtronic. Ann Intern Med (2013) 1.45
Do imaging studies performed in physician offices increase downstream utilization?: an empiric analysis of cardiac stress testing with imaging. JACC Cardiovasc Imaging (2011) 1.44
Evaluation of the Mobile Acute Care of the Elderly (MACE) service. JAMA Intern Med (2013) 1.43
Relationships with the drug industry: More regulation, greater transparency. BMJ (2009) 1.38
Differential peeky bias. Int J Occup Environ Health (2006) 1.37
A model for dissemination and independent analysis of industry data. JAMA (2011) 1.35
Influence of patients' socioeconomic status on clinical management decisions: a qualitative study. Ann Fam Med (2008) 1.34
Pharmaceutical industry marketing: understanding its impact on women's health. Obstet Gynecol Surv (2008) 1.21
Scheduled and unscheduled hospital readmissions among patients with diabetes. Am J Manag Care (2010) 1.18
Adherence of pharmaceutical advertisements in medical journals to FDA guidelines and content for safe prescribing. PLoS One (2011) 1.16
Skilled nursing facility referral and hospital readmission rates after heart failure or myocardial infarction. Am J Med (2012) 1.16
Regional variation in cardiac catheterization appropriateness and baseline risk after acute myocardial infarction. J Am Coll Cardiol (2008) 1.14
Time to publication among completed clinical trials. JAMA Intern Med (2013) 1.13
The relationship between systolic blood pressure on admission and mortality in older patients with heart failure. Eur J Heart Fail (2010) 1.12
Sea change in open science and data sharing: leadership by industry. Circ Cardiovasc Qual Outcomes (2014) 1.05
Development and use of an administrative claims measure for profiling hospital-wide performance on 30-day unplanned readmission. Ann Intern Med (2014) 1.05
Beyond insurance coverage: usual source of care in the treatment of hypertension and hypercholesterolemia. Data from the 2003-2006 National Health and Nutrition Examination Survey. Am Heart J (2010) 1.03
Impact of state laws that extend eligibility for parents' health insurance coverage to young adults. Pediatrics (2012) 1.01
What is different about the market for health care? JAMA (2007) 1.01
Use of preventive care by elderly male veterans receiving care through the Veterans Health Administration, Medicare fee-for-service, and Medicare HMO plans. Am J Public Health (2007) 1.00
The use and misuse of thrombolytic therapy within the Veterans Health Administration. Med Care (2012) 1.00
Association of chronic diseases and impairments with disability in older adults: a decade of change? Med Care (2012) 1.00
Impact of the 2008 US Preventive Services Task Force recommendation to discontinue prostate cancer screening among male Medicare beneficiaries. Arch Intern Med (2012) 0.99
A measure of care coordination? J Gen Intern Med (2013) 0.98
Persistence of cardiovascular risk after rofecoxib discontinuation. Arch Intern Med (2010) 0.98
On Chlorofluorocarbon Bans and Inhaled Albuterol Prices. JAMA Intern Med (2015) 0.96
The cost implications of prostate cancer screening in the Medicare population. Cancer (2013) 0.95
Appropriate proton pump inhibitor use among older adults: a retrospective chart review. Am J Geriatr Pharmacother (2008) 0.95
Financial stress and outcomes after acute myocardial infarction. PLoS One (2012) 0.95
Hospital-based, acute care use among patients within 30 days of discharge after coronary artery bypass surgery. Ann Thorac Surg (2013) 0.94
Association between physician quality improvement incentives and ambulatory quality measures. Am J Manag Care (2012) 0.93
Audit and feedback: an intervention to improve discharge summary completion. J Hosp Med (2011) 0.93
Is P4P really FFS? JAMA (2007) 0.92
Description of a research-based health activism curriculum for medical students. J Gen Intern Med (2006) 0.90
Visits for primary care services to primary care and specialty care physicians, 1999 and 2007. Arch Intern Med (2012) 0.89
Usual source of care and outcomes following acute myocardial infarction. J Gen Intern Med (2014) 0.89
Revisiting Essure--Toward Safe and Effective Sterilization. N Engl J Med (2015) 0.88
Trends and clinical implications of preoperative breast MRI in Medicare beneficiaries with breast cancer. Breast Cancer Res Treat (2013) 0.87
Age-based and sex-based disparities in screening colonoscopy use among medicare beneficiaries. J Clin Gastroenterol (2013) 0.87
Direct-to-consumer television advertising: time to turn off the tube? J Gen Intern Med (2013) 0.87
High incarceration rates among black men enrolled in clinical studies may compromise ability to identify disparities. Health Aff (Millwood) (2014) 0.87
Use of Medicare and Department of Veterans Affairs health care by veterans with dementia: a longitudinal analysis. J Am Geriatr Soc (2009) 0.87
Ethics, morality, and conflicting interests: how questionable professional integrity in some scientists supports global corporate influence in public health. Int J Occup Environ Health (2015) 0.86
Marketing to physicians in a digital world. N Engl J Med (2014) 0.86
Prevalence of inadequate blood pressure control among veterans after acute ischemic stroke hospitalization: a retrospective cohort. Circ Cardiovasc Qual Outcomes (2011) 0.85
Regional density of cardiologists and rates of mortality for acute myocardial infarction and heart failure. Circ Cardiovasc Qual Outcomes (2013) 0.85
A random effects multinomial logit analysis of using Medicare and VA healthcare among veterans with dementia. Home Health Care Serv Q (2010) 0.84
Trial-results reporting and academic medical centers. N Engl J Med (2015) 0.84
Reporting discrepancies between the clinicaltrials.gov results database and peer-reviewed publications. Ann Intern Med (2014) 0.84
Self-reported and actual beta-blocker prescribing for heart failure patients: physician predictors. PLoS One (2009) 0.83
Laboratory test ordering at physician offices with and without on-site laboratories. J Gen Intern Med (2010) 0.83
Updated estimates of pharmaceutical company payments to physicians in Vermont. JAMA (2008) 0.83
US cardiologist workforce from 1995 to 2007: modest growth, lasting geographic maldistribution especially in rural areas. Health Aff (Millwood) (2011) 0.83
Who is missing from the measures? Trends in the proportion and treatment of patients potentially excluded from publicly reported quality measures. Am Heart J (2010) 0.83
Preventive Care Quality of Medicare Accountable Care Organizations: Associations of Organizational Characteristics With Performance. Med Care (2016) 0.83
Corporate versus public interests: community responsibility to defend scientific integrity. Int J Occup Environ Health (2011) 0.81
Variation in US hospital emergency department admission rates by clinical condition. Med Care (2015) 0.80
Switching from rosiglitazone: thinking outside the class. JAMA (2011) 0.79
Determinants of cardiac catheterization use in older Medicare patients with acute myocardial infarction. Circ Cardiovasc Qual Outcomes (2009) 0.79